Abstract
The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Current Drug Targets
Title:Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Volume: 14 Issue: 6
Author(s): Xuli Zhao, Ye Yue, Wengxiang Cheng, Jingchao Li, Yiping Hu, Ling qin and Peng Zhang
Affiliation:
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Abstract: The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Export Options
About this article
Cite this article as:
Zhao Xuli, Yue Ye, Cheng Wengxiang, Li Jingchao, Hu Yiping, qin Ling and Zhang Peng, Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060010
DOI https://dx.doi.org/10.2174/1389450111314060010 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
QbD-Enabled Systematic Development of Ileo-Colonic Targeted Novel Mucoadhesive Microspheres of Flurbiprofen
Current Drug Delivery Targeting Cytokines as an Approach to Modulate Allergic Diseases: The Clinical Experience
Medicinal Chemistry Reviews - Online (Discontinued) The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Nanocarriers for Gene Delivery - Polymer Structure, Targeting Ligands and Controlled-Release Devices
Current Nanoscience Editorial [Hot topic: Drug Targeting of Autoimmunity (Guest Editor: Manfred Kunz)]
Current Drug Discovery Technologies Application of Transcriptome Analysis to Clinical Pharmacology Studies
Current Molecular Medicine Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
Clinical Cancer Drugs Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy The Use of Biologics for Psoriasis in Asia-Pacific Region
Current Rheumatology Reviews Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Anti-Arthritic Effect of Garcinol Enriched Fraction Against Adjuvant Induced Arthritis
Recent Patents on Inflammation & Allergy Drug Discovery Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Protein Kinase A (PKA) - A Potential Target for Therapeutic Intervention of Dysfunctional Immune Cells
Current Drug Targets Salmonella as Live Trojan Horse for Vaccine Development and Cancer Gene Therapy
Current Gene Therapy Cytokines as Targets in Chronic Obstructive Pulmonary Disease
Current Drug Targets